chartexchange

CVM
Cel-Sci Corporation
stockNYSEAMERICAN

At CloseNov 18, 2026 3:53:37 PM EST
1.40USD-24.324%(-0.45)613,008
Pre-marketNov 18, 2026 9:08:30 AM EST
1.7011USD-8.049%(-0.1489)
After-hoursNov 18, 2026 4:58:30 PM EST
1.36USD-2.857%(-0.04)
Loading…
Loading…
Healthcare
Biotechnology
CEO
Geert Kersten
HQ
Vienna, VA, USA
Previous Close
$1.85
Beta
0.78
52-Week High
$7.80 2025-11-28
52-Week Low
$0.89 2026-05-12
SMA 50
$1.67
SMA 200
$2.26
Avg. Vol 10D
339,771
Avg. Vol 30D
235,864
Avg. Vol 90D
233,904
Relative Vol
2.61
16.37M
4.1300%
1,730
Jan 4, 2027 (46d)
May 20, 2025 · 1-for-30 (reverse)
CVM Profile

cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.

CVM Performance
PeriodPriceDateChangeBeta
1W1.312026-11-11+5.34%-19.638
1M1.652026-10-19-16.36%-1.750
3M1.592026-08-18-13.21%-0.759
6M1.722026-05-18-19.77%-0.005
1Y6.692025-11-18-79.37%0.784
2Y16.932024-11-18-91.85%—
5Y314.402021-11-18-99.56%1.110
CVM Stock Summary

Cel-Sci Corporation (NYSEAMERICAN:CVM) stock price today is $1.38, and today's volume is 615,783. CVM is down 25.405% today. The 30 day average volume is 235,864. CVM market cap is $24.27M with 17.59M shares outstanding.